The Effect of the GM-CSF Gel on the Endometrial Thickness in Infertile Women With Thin Endometrium

Overview

The purpose of this study is to investigate the efficacy of the granulocyte-macrophage colony stimulating factor(GM-CSF) gel on the endometrial thickness in infertile women with thin endometrium.

Full Title of Study: “A Randomized Controlled Trial of the Effect of the Granulocyte-macrophage Colony Stimulating Factor Gel on the Endometrial Thickness in Infertile Women With Thin Endometrium”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: June 2020

Detailed Description

The thin endometrium is detrimental to embryo implantation, probability of clinical pregnancy for an endometrial thickness ≤ 7 mm was significantly lower compared with cases with endometrial thickness > 7 mm. It has been reported the granulocyte colony stimulating factor (G-CSF) increased the endometrial thickness and pregnancy rate of infertile women with thin endometrium during IVF cycle. However, most of the researches were retrospective and small sample size, and the results were conflicted among them. GM-CSF is another member of CSF superfamily, recalling more macrophage than G-CSF, which could be more effective in local homeostasis maintain and wound repair. GM-CSF has been widely used in skin repair after burn. It was also found the GM-CSF and its receptor in endometrium. In the past year, the investigators tried GM-CSF irrigation in 21 women with thin endometrium and most of them received GM-CSF after hysteroscopic examination or slight adhesion relaxing, and the preliminary data suggested that the GM-CSF may promote the endometrial growth. Does the GM-CSF gel can improve the endometrial thickness? Therefore, this study was conducted.

Interventions

  • Drug: GM-CSF
    • 3ml GM-CSF gel will be irrigated into the uterine cavity immediately when hysteroscopy is complete. Then same dose gel will be given every other day twice
  • Drug: 17-ß estradiol
    • A hormone replace treatment by 17-ß estradiol (6mg per day) follows next cycle to prepare for embryo transfer

Arms, Groups and Cohorts

  • Experimental: GM-CSF
    • Hysteroscopy will be arranged to confirm the uterine cavity is normal and there is no significant intrauterine adhesion. 3ml GM-CSF gel will be irrigated into the uterine cavity immediately when hysteroscopy is complete. Then same dose gel will be given every other day twice.
  • Experimental: Control
    • Hysteroscopy will be arranged to confirm the uterine cavity is normal and there is no significant intrauterine adhesion. After hysteroscopy examination, nothing was applied to the uterine cavity.

Clinical Trial Outcome Measures

Primary Measures

  • the endometrial thickness
    • Time Frame: 1 months after hysteroscopy examination
    • the endometrial thickness following the hormonal replacement treatment evaluated based on the ultrasound

Secondary Measures

  • embryo transfer cancelation rate
    • Time Frame: 2 months after hysteroscopy examination
    • according to the patients’ wishes
  • uterine artery blood supply markers
    • Time Frame: 1 months after hysteroscopy examination
    • uterine artery blood supply markers, such as PI, reflux index(RI) and S/D, evaluated based on the 3-D ultrasonography
  • pregnancy rate
    • Time Frame: 3 months after hysteroscopy examination
    • pregnancy rate after frozen embryo transfer

Participating in This Clinical Trial

Inclusion Criteria

1. Woman undergoes IVF treatment, 18-40 years old 2. The endometrial thickness <7mm on the day of human chorionic gonadotropin during IVF or after taking oral estradiol valerate 6mg/d for 14 days. 3. Embryo transfer is cancelled because of thin endometrium 4. No intrauterine adhesion according to the 3-D ultrasonography Exclusion Criteria:

1. Systemic diseases unable to conceive 2. Chromasome abnormal 3. History of G-CSF or GM-CSF allergy or untoward effect 4. Thin endometrium related to clomid 5. Severe or moderate uterine adhesion 6. The influence factor of embryo implantation: hydrosalpinx, endometriosis, adenomyosis,myoma of uterus 7. Uterine malformation, adenomyosis, uterine leiomyoma sized more than 2cm. 8. Patients who is allergic to granulocyte-macrophage colony stimulating factor 9. Patients with inflammation of reproductive organs, pelvic cavity inflammation, malignant tumor of reproductive organs and other systemic diseases that could cause metrorrhagia

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 40 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Sir Run Run Shaw Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Xiaona Lin, Vice Director of gynaecology and obstetrics – Sir Run Run Shaw Hospital
  • Overall Official(s)
    • Xiaona Lin, Doctor, Study Director, Sir Run Run Shaw Hospital
  • Overall Contact(s)
    • Xiaona Lin, Doctor, +8657186006252, linna73@263.net

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.